GRACE THERAPEUTICS INC (GRCE) Stock Fundamental Analysis

NASDAQ:GRCE • US00439U1043

4.29 USD
+0.17 (+4.13%)
At close: Feb 27, 2026
4.3485 USD
+0.06 (+1.36%)
After Hours: 2/27/2026, 8:07:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, GRCE scores 3 out of 10 in our fundamental rating. GRCE was compared to 192 industry peers in the Pharmaceuticals industry. While GRCE has a great health rating, there are worries on its profitability. GRCE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year GRCE has reported negative net income.
  • GRCE had a negative operating cash flow in the past year.
  • In the past 5 years GRCE always reported negative net income.
  • GRCE had a negative operating cash flow in each of the past 5 years.
GRCE Yearly Net Income VS EBIT VS OCF VS FCFGRCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of GRCE (-8.73%) is better than 69.27% of its industry peers.
  • The Return On Equity of GRCE (-9.21%) is better than 76.04% of its industry peers.
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
GRCE Yearly ROA, ROE, ROICGRCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCE Yearly Profit, Operating, Gross MarginsGRCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, GRCE has more shares outstanding
  • The number of shares outstanding for GRCE has been increased compared to 5 years ago.
  • GRCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRCE Yearly Shares OutstandingGRCE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GRCE Yearly Total Debt VS Total AssetsGRCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • GRCE has an Altman-Z score of 5.76. This indicates that GRCE is financially healthy and has little risk of bankruptcy at the moment.
  • GRCE's Altman-Z score of 5.76 is fine compared to the rest of the industry. GRCE outperforms 77.08% of its industry peers.
  • There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.76
ROIC/WACCN/A
WACCN/A
GRCE Yearly LT Debt VS Equity VS FCFGRCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 14.96 indicates that GRCE has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 14.96, GRCE belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
  • A Quick Ratio of 14.96 indicates that GRCE has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 14.96, GRCE belongs to the best of the industry, outperforming 85.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.96
Quick Ratio 14.96
GRCE Yearly Current Assets VS Current LiabilitesGRCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.21% over the past year.
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GRCE will show a very strong growth in Earnings Per Share. The EPS will grow by 31.37% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y3.39%
EPS Next 5Y31.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCE Yearly Revenue VS EstimatesGRCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
GRCE Yearly EPS VS EstimatesGRCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GRCE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCE Price Earnings VS Forward Price EarningsGRCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCE Per share dataGRCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.59%
EPS Next 3Y3.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GRCE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRACE THERAPEUTICS INC

NASDAQ:GRCE (2/27/2026, 8:07:39 PM)

After market: 4.3485 +0.06 (+1.36%)

4.29

+0.17 (+4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)06-26
Inst Owners19.66%
Inst Owner ChangeN/A
Ins Owners3.21%
Ins Owner ChangeN/A
Market Cap66.37M
Revenue(TTM)N/A
Net Income(TTM)-5.98M
Analysts82.5
Price Target11.73 (173.43%)
Short Float %0.36%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.59%
Min EPS beat(2)50.98%
Max EPS beat(2)68.2%
EPS beat(4)4
Avg EPS beat(4)64.31%
Min EPS beat(4)6.42%
Max EPS beat(4)131.63%
EPS beat(8)7
Avg EPS beat(8)46.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS4.19
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.96
Quick Ratio 14.96
Altman-Z 5.76
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y3.39%
EPS Next 5Y31.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.02%
EBIT Next 3Y-0.55%
EBIT Next 5YN/A
FCF growth 1Y35.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.61%
OCF growth 3YN/A
OCF growth 5YN/A

GRACE THERAPEUTICS INC / GRCE FAQ

What is the fundamental rating for GRCE stock?

ChartMill assigns a fundamental rating of 3 / 10 to GRCE.


What is the valuation status of GRACE THERAPEUTICS INC (GRCE) stock?

ChartMill assigns a valuation rating of 0 / 10 to GRACE THERAPEUTICS INC (GRCE). This can be considered as Overvalued.


How profitable is GRACE THERAPEUTICS INC (GRCE) stock?

GRACE THERAPEUTICS INC (GRCE) has a profitability rating of 1 / 10.


How financially healthy is GRACE THERAPEUTICS INC?

The financial health rating of GRACE THERAPEUTICS INC (GRCE) is 8 / 10.